Key result
Elevated serum copeptin identifies poor glycemic control and diabetic kidney disease in T2DM with AUC >0.92.
Why the study?
Serum copeptin is a potential biomarker, but its usefulness as a marker of glycemic status and its correlation with diabetic kidney disease in T2DM required evaluation.
Does serum copeptin accurately identify poor glycemic control and diabetic kidney disease in patients with type 2 diabetes?
Cross-Sectional (n=60)
No
Does serum copeptin accurately identify poor glycemic control and diabetic kidney disease in patients with type 2 diabetes?
Effect estimate: For poor glycemic control: ROC AUC 0.925, sensitivity 90%, specificity 95% at cutoff >3452 pg/mL; For diabetic kidney disease: ROC AUC 0.94, sensitivity 95%, specificity 90% at cutoff >370 pg/mL
p-value: p=<0.001 for comparisons of copeptin levels between groups
Serum copeptin serves as a highly sensitive dual biomarker for identifying both poor glycemic control and diabetic kidney disease in patients with type 2 diabetes.
Copeptin may mark poor glycemic control and DKD in T2DM; hypothesis-generating and requires prospective validation before clinical use.
Chronic kidney disease and end-stage renal disease are significantly contributed by diabetes mellitus (DM), especially diabetes mellitus type 2 (T2DM). A stable surrogate marker of vasopressin, the serum copeptin, has become a potential biomarker of poor glycemic control and diabetic kidney disease (DKD). The research objective is to estimate the usefulness of the serum copeptin as a marker of glycemic status and its correlation with DKD in patients with T2DM. This cross-sectional study was conducted on 60 participants at Cairo University Hospital between 2021 and 2022. Participants were divided into 40 T2DM patients (26 males, 14 females; mean age 52.62 ± 9.7 years) and 20 healthy controls. Diabetic patients were further categorized into controlled (HbA1c ≤ 7%, n = 18) and uncontrolled (HbA1c > 7%, n = 22) subgroups. Clinical evaluation, biochemical tests, and serum copeptin levels (measured via ELISA) were analyzed. Cairo university, Faculty of Medicine, Ethical approval: N-247-2023. Serum copeptin levels were significantly higher in diabetic patients compared to controls (p < 0.001), and in uncontrolled vs. controlled diabetics (p < 0.001). Copeptin positively correlated with fasting glucose, HbA1c, serum creatinine, and urinary protein, and negatively with eGFR. ROC analysis identified copeptin as a sensitive marker for both poor glycemic control at a cut off value > 3452 pg/mL (AUC 0.925) and DKD at a cut off vlue > 370 pg/mL (AUC 0.94), both with high sensitivity and specificity. The level of serum copeptin correlates positively with poor glycemic status as well as DKD among T2DM patients. It can be an effective, non-invasive biomarker used in early diagnosis and risk stratification of diabetic complications. Not applicable.
No takes yet. Share an insight, caveat, or question.
Rakha et al. (2026) conducted a cross-sectional in Adults with type 2 diabetes mellitus with disease duration >5 years (mean age 52.62±9.7 years) versus healthy controls (n=60). Measurement of serum copeptin levels vs. Healthy control group; controlled vs uncontrolled diabetes subgroups was evaluated on Association of serum copeptin levels with poor glycemic control (HbA1c >7%) and diabetic kidney disease (DKD) defined by renal impairment (elevated creatinine, proteinuria, reduced eGFR) (For poor glycemic control: ROC AUC 0.925, sensitivity 90%, specificity 95% at cutoff >3452 pg/mL; For diabetic kidney disease: ROC AUC 0.94, sensitivity 95%, specificity 90% at cutoff >370 pg/mL, p=<0.001 for comparisons of copeptin levels between groups). Serum copeptin levels were significantly higher in type 2 diabetic patients compared to controls (p<0.001), and in uncontrolled vs controlled diabetics, with ROC AUCs 0.925 and 0.94 for predicting poor glycemic control and diabetic kidney disease respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: